Key Points
- CEO Peter Blume-Jensen bought 49,000 ACRV shares on Jan. 14 at $1.68 each (total $82,320), boosting his direct stake to 2,095,771 shares — a 2.39% increase — as disclosed in an SEC Form 4 filing.
- Acrivon shares rose about 5.9% and opened at $1.98; the company has a market cap of roughly $62.5 million, negative EPS, and a 12-month trading range of $1.05 to $8.00.
- Analyst sentiment is mixed but leans positive overall with a consensus Moderate Buy and an average price target of $11.67, while individual ratings span from sell to buy (notably Piper Sandler $8 and HC Wainwright $19).
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average price of $1.70 per share, for a total transaction of $15,014.40. Following the completion of the acquisition, the chief financial officer owned 20,983 shares in the company, valued at approximately $35,671.10. This trade represents a 72.69% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Acrivon Therapeutics Stock Performance
Acrivon Therapeutics stock opened at $1.98 on Friday. Acrivon Therapeutics, Inc. has a one year low of $1.05 and a one year high of $8.00. The stock's 50 day moving average price is $2.30 and its 200 day moving average price is $1.82. The firm has a market capitalization of $62.48 million, a PE ratio of -0.93 and a beta of 1.73.
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.10. On average, analysts forecast that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently weighed in on ACRV shares. Wall Street Zen downgraded Acrivon Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, January 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Acrivon Therapeutics in a report on Monday, December 29th. HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Finally, Piper Sandler upped their target price on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Acrivon Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $11.67.
Read Our Latest Research Report on Acrivon Therapeutics
Institutional Trading of Acrivon Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of ACRV. Focus Partners Wealth bought a new position in Acrivon Therapeutics during the 3rd quarter worth approximately $36,000. Quadrature Capital Ltd bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at approximately $26,000. Invesco Ltd. acquired a new stake in shares of Acrivon Therapeutics during the 1st quarter valued at approximately $72,000. Algert Global LLC bought a new position in Acrivon Therapeutics during the third quarter worth $81,000. Finally, XTX Topco Ltd bought a new position in Acrivon Therapeutics during the second quarter worth $126,000. Institutional investors and hedge funds own 71.62% of the company's stock.
Acrivon Therapeutics Company Profile
(
Get Free Report)
Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.
The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
